Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2020156982 - MONOHYDRATE DE CHLORHYDRATE DE ROGARATINIB ET ÉTATS SOLIDES ASSOCIÉS


Avertissement La version image (PDF) disponible dans PATENTSCOPE est la version officielle. Cette version HTML en ligne est fournie pour aider les utilisateurs. Malgré le grand soin apporté à la compilation pour assurer une représentation précise et exacte des données figurant sur le document/les images imprimés, des erreurs et/ou des omissions ne peuvent pas être exclues en raison des processus de transmission et de conversion de données et des limitations inhérentes aux processus de traduction (éventuellement) automatique utilisés. Les liens hypertexte suivis de ce symbole sont associés à des ressources externes qui ne sont pas contrôlées par l'OMPI. L'OMPI décline toute responsabilité concernant les points mentionnés ci-dessus.

INTERNATIONAL SEARCH REPORT (ISR)
Part 1:  1  2  3  4  5  6          Part 2:  A  B  C  D  E 
International application No. Applicant's or agent's file reference
PCT/EP2020/051884 BHC183045-WO
International filing date (day/month/year) (Earliest) Priority Date (day/month/year)
27 January 2020 31 January 2019
Applicant
BAYER AKTIENGESELLSCHAFT
FOR FURTHER ACTION: See Form PCT/ISA/220 as well as, where applicable, item 5 below.
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.
It is also accompanied by a copy of each prior art document cited in this report.
1. Basis of the report
a. With regard to the language, the international search was carried out on the basis of:
the international application in the language in which it was filed.
a translation of the international application into                                          which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
b.
This international search report has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).
c.
With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
2. Certain claims were found unsearchable
3. Unity of invention is lacking
4. Title of the invention
The text is approved as submitted by the applicant.
The text has been established by this Authority to read as follows:
THE MONOHYDRATE OF ROGARATINIB HYDROCHLORIDE AND SOLID STATES THEREOF

5. Abstract
The text is approved as submitted by the applicant.
The text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

Compound (III) which is the crystalline form of [4-{[4-amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-l-benzothiophen-2-yl)pyrrolo[2, -f] [ 1,2,4]triazin-7-yl]methyl}piperazin-2-one hydrochloride] which is the monohydrate, processes for its preparation, pharmaceutical compositions comprising it and its use in the control of disorders, including cancer.


6. Drawings
a.
The figure of the drawings to be published with the abstract is Figure No. ____________
as suggested by the applicant.
as selected by this Authority, because the applicant failed to suggest a figure.
as selected by this Authority, because this figure better characterizes the invention.
b.
none of the figures is to be published with the abstract.

A. CLASSIFICATION OF SUBJECT MATTER

     C07D 487/04 (2006.01)i; A61K 31/53 (2006.01)i; A61P 35/00 (2006.01)i
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols):
     C07D
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used):
EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
(1)
A
WO 2013087578 A1 (BAYER PHARMA AG [DE]; BAYER IP GMBH [DE]) 20 June 2013 (2013-06-20)
1-18
cited in the application
examples 1-2
(2)
A
MARIE-PIERRE COLLIN ET AL, "Discovery of Rogaratinib (BAY 1163877): a pan-FGFR Inhibitor", CHEMMEDCHEM,Vol. 13, No. 5, 06 March 2018 (2018-03-06), page 437-445,
XP055523635
1-18
abstract
*
Special categories of cited documents:
"A"
document defining the general state of the art which is not considered to be of particular relevance
"D"
document cited by the applicant in the international application
"E"
earlier application or patent but published on or after the international filing date
"L"
document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"
document referring to an oral disclosure, use, exhibition or other means
"P"
document published prior to the international filing date but later than the priority date claimed
"T"
later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"
document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"
document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"
document member of the same patent family

D. INFORMATION ON PATENT FAMILY MEMBERS

Patent document cited in search report Publication date
(day/month/year)
Patent family member(s) Publication date
(day/month/year)
WO 2013087578 A1
20 June 2013
AR 089207 A1
AU 2012350750 A1
AU 2017206140 A1
AU 2019204255 A1
BR 112014014531 A2
CA 2859133 A1
CL 2014001547 A1
CN 104245700 A
CO 7030961 A2
CR 20140288 A
CU 20140065 A7
CU 20160039 A7
CY 1118112 T1
DK 2791140 T3
DO P2014000127 A
EA 201400707 A1
EP 2791140 A1
ES 2591203 T3
GT 201400113 A
HK 1205123 A1
HR P20161130 T1
HU E029582 T2
IL 232611 A
JO 3295 B1
JP 6050829 B2
JP 2015500307 A
KR 20140103328 A
LT 2791140 T
ME 02517 B
MX 367158 B
NZ 625073 A
PE 20141855 A1
PH 12014501355 A1
PL 2791140 T3
PT 2791140 T
SG 11201402325Q A
TN 2014000255 A1
TW 201339162 A
UA 116768 C2
US 2013158000 A1
US 2014336173 A1
US 2019016724 A1
UY 34484 A
WO 2013087578 A1
ZA 201405140 B
06 August 2014
12 June 2014
03 August 2017
04 July 2019
06 August 2019
20 June 2013
24 October 2014
24 December 2014
21 August 2014
14 July 2014
27 November 2014
31 August 2016
28 June 2017
19 September 2016
15 August 2014
28 November 2014
22 October 2014
25 November 2016
25 August 2015
11 December 2015
18 November 2016
28 March 2017
29 May 2017
16 September 2018
21 December 2016
05 January 2015
26 August 2014
10 October 2016
20 February 2017
07 August 2019
29 July 2016
26 November 2014
22 September 2014
31 August 2017
20 September 2016
26 September 2014
30 September 2015
01 October 2013
10 May 2018
20 June 2013
13 November 2014
17 January 2019
31 July 2013
20 June 2013
26 April 2017
Name and mailing address of the ISA/:
European Patent Office
P.B. 5818, Patentlaan 2, 2280 HV Rijswijk,
Netherlands
Telephone No. (+31-70)340-2040
Facsimile No. (+31-70)340-3016
Date of the actual completion of the international search:
04 March 2020
Date of mailing of the international search report:
17 March 2020
Authorized officer:
Gettins, Marc
Top    Part 1: 1 2 3 4 5 6         Part 2: A B C D E